FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.

GLP-1T — Published Research

Reviewed by: Dr. Sarah Chen, PharmD| Last updated: abril 9, 2026|For laboratory reference only

← Back to GLP-1T product page

Ver reportes de laboratorio · Calidad y pruebas · Preguntas frecuentes

Biblioteca de investigación

Published research on this compound — for educational purposes only

Mechanism as an imbalanced dual agonist

GLP-1T is characterized as an “imbalanced” dual agonist because it displays full agonism at the GIP receptor but biased agonism at the GLP-1 receptor. At the GLP-1R, GLP-1T preferentially activates Gαs-mediated cAMP signaling while exhibiting reduced β-arrestin recruitment compared to native GLP-1. This biased signaling profile results in less receptor internalization and potentially sustained receptor surface availability. The compound’s C-20 fatty diacid moiety enables albumin binding and alters its stability profile in preclinical characterization. Research compound — not for human use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

GLP-1R signaling vs selective GLP-1 agonists

Unlike selective GLP-1 receptor agonists such as GLP-1 S, GLP-1T demonstrates biased agonism at GLP-1R characterized by reduced β-arrestin-1 recruitment. Selective GLP-1 agonists activate both cAMP and β-arrestin pathways with relatively balanced efficacy, leading to robust receptor internalization. GLP-1T’s biased profile — favoring cAMP over β-arrestin — may alter receptor trafficking dynamics. The simultaneous engagement of GIP receptors with full agonism distinguishes GLP-1T’s pharmacological signature from mono-agonist compounds. Research compound — not for human use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

cAMP vs β-arrestin receptor pharmacology

In cell-based assays, GLP-1T activates GIP receptor-mediated cAMP accumulation with potency comparable to native GIP. At the GLP-1 receptor, GLP-1T generates cAMP with approximately 5-fold lower potency than native GLP-1, but displays markedly reduced (>100-fold) β-arrestin-1 and β-arrestin-2 recruitment. This dissociation between G-protein signaling and arrestin recruitment defines GLP-1T as a G-protein-biased agonist at GLP-1R. Research compound — not for human use.

Willard FS, et al. JCI Insight. 2020;5(17):e140532. JCI Insight

Structural basis for dual receptor engagement

GLP-1T is a 39-amino acid linear peptide based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. Key structural features include an α-aminoisobutyric acid (Aib) substitution at position 2 conferring DPP-4 resistance, and a C-20 fatty diacid moiety conjugated via a linker at lysine-20 enabling non-covalent albumin binding. The exendin-4-derived C-terminal extension (positions 35-39) contributes to GLP-1R engagement. Research compound — not for human use.

Min Q, et al. Proc Natl Acad Sci USA. 2022;119(34):e2116506119. PNAS

Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.

Reviewed by

Dr. Sarah Chen, PharmD

Research pharmacologist specializing in peptide chemistry and literature analysis. Reviews analytical, in vitro, and preclinical research for accuracy and completeness.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD y Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for laboratory research use. This page is not intended as dosing, administration, treatment, or other human-use guidance.